Ampio Pharma craters on FDA setback but plans to fight back

The FDA has asked Ampio Pharma to conduct another clinical trial for its osteoarthritis med, Ampion, setting back its BLA and sending its stock down 79% on Wednesday and another 26% in premarket trading.